Tianjin Pharmaceutical Da Ren Tang Group (SHA:600329, SGX:T14) approved the sale of a 13% stake in Tianjin TSKF Pharma to Haleon China for 1.75 billion yuan, according to a filing with the Singapore Exchange on Friday.
Following the sale of shares, the company will retain a 12% stake in the company.
Shares of the pharmaceutical company surged nearly 10% in China and nearly 7% in Singapore in recent trade.
Price (SGD): S$35.36, Change: S$+3.1, Percent Change: +9.58%
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。